Microbiome-Targeted Therapies as an Adjunct to Traditional Weight Loss Interventions: A Systematic Review and Meta-Analysis
Tina Peckmezian,Vanessa Garcia-Larsen,Kayla Wilkins,Rana H Mosli,Nasser F BinDhim,George Kunnackal John,Muhammad Yasir,Esam Ibraheem Azhar,Gerard E Mullin,Saleh A Alqahtani
DOI: https://doi.org/10.2147/DMSO.S378396
2022-12-11
Abstract:Tina Peckmezian, 1 Vanessa Garcia-Larsen, 2 Kayla Wilkins, 3 Rana H Mosli, 4 Nasser F BinDhim, 5– 7 George Kunnackal John, 8 Muhammad Yasir, 9, 10 Esam Ibraheem Azhar, 9, 10 Gerard E Mullin, 11 Saleh A Alqahtani 11, 12 1 Independent Scholar, Sydney, NSW, Australia; 2 Program in Human Nutrition, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 3 Environmental GeoScience Research Group, Trent University, Peterborough, ON, Canada; 4 Clinical Nutrition Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia; 5 Sharik Association for Health Research, Riyadh, Saudi Arabia; 6 College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; 7 Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 8 Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Easton, MD, USA; 9 Special Infectious Agents Unit – BSL3, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; 10 Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia; 11 Liver Transplant Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; 12 Division of Gastroenterology & Hepatology, John Hopkins University, Baltimore, MD, USA Correspondence: Saleh A Alqahtani, Liver Transplant Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, Email Objective: This study evaluated the effect of microbiome-targeted therapies (pre-, pro-, and synbiotics) on weight loss and other anthropometric outcomes when delivered as an adjunct to traditional weight loss interventions in overweight and obese adults. Methods: A systematic review of three databases (Medline [PubMed], Embase, and the Cochrane Central Register of Controlled Trials) was performed to identify randomized controlled trials published between January 1, 2010 and December 31, 2020, that evaluated anthropometric outcomes following microbiome-targeted supplements in combination with dietary or dietary and exercise interventions. The pooled mean difference (MD) between treatment and control groups was calculated using a random effects model. Results: Twenty-one trials with 1233 adult participants (76.4% female) with overweight or obesity were included. Separate meta-analyses were conducted for probiotics (n=11 trials) and synbiotics (n=10 trials) on each anthropometric outcome; prebiotics were excluded as only a single study was found. Patient characteristics and methodologies varied widely between studies. All studies incorporated some degree of caloric restriction, while only six studies included recommendations for adjunct exercise. Compared with dietary or dietary and exercise interventions only, probiotics resulted in reductions in body weight (MD: − 0.73 kg; 95% confidence interval [CI]: − 1.02 to − 0.44, p < 0.001), fat mass (MD: − 0.61 kg; 95% CI: − 0.77 to − 0.45; p< 0.001) and waist circumference (MD: − 0.53 cm; 95% CI: − 0.99 to − 0.07, p=0.024) while synbiotics resulted in reductions in fat mass (MD: − 1.53 kg; 95% CI: − 2.95 to − 0.12, p=0.034) and waist circumference (MD: − 1.31 cm; 95% CI: − 2.05 to − 0.57, p< 0.001). Conclusion: This analysis indicates that microbiome-targeted supplements may enhance weight loss and other obesity outcomes in adults when delivered as an adjunct to dietary or dietary and exercise interventions. Personalized therapy to include microbiome-targeted supplements may help to optimize weight loss in overweight and obese individuals. Keywords: microbiome, obesity, adjunctive therapy, weight loss Obesity is one of the most widespread chronic diseases worldwide. According to the World Health Organization (WHO), global rates of obesity have nearly tripled since 1975, with over 650 million adults estimated to have obesity in 2016. 1 Obesity was associated with 4.7 million deaths in 2017 worldwide, and by 2025, more than 1 billion adults are predicted to be obese, with 177 million developing severe conditions. 2,3 Excessive adiposity is associated with impaired quality of life and a myriad of comorbidities that collectively heighten the risk of preventable mortality. 4,5 Identifying therapeutic options that accelerate weight loss or reduce the consequences of obesity is therefore of great importance. A multitude of treatment approaches have been trialed to facilitate weight loss. Obesity management often begins with lif -Abstract Truncated-